Eli Lilly and Company
) shares were up 0.8% after the company announced encouraging
data from the sixth phase III AWARD (Assessment of Weekly
AdministRation of LY2189265 in Diabetes) study on its diabetes
candidate, dulaglutide. Overall, the stock price has increased
1.1% on the news.
The randomized, open-label, parallel-arm AWARD-6 study (n = 599)
compared the efficacy of once-weekly dulaglutide to that of
) once-daily Victoza in patients suffering from type II diabetes,
who are on metformin.
At 26 weeks, dulaglutide 1.5 mg showed non-inferiority to Victoza
1.8 mg in the reduction of HbA1c (hemoglobin A1c) levels and met
the primary endpoint of the study. Earlier, in the five AWARD
trials, dulaglutide has shown superior efficacy in reducing HbA1c
levels when compared to placebo and other active comparators.
Eli Lilly has already submitted marketing applications for
dulaglutide to the U.S. Food and Drug Administration (FDA) and
the European Medicines Agency (EMA).
Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1)
receptor agonist being developed as a once-weekly treatment for
type II diabetes. We are encouraged with the results from the
AWARD-6 study. We believe the dulaglutide once-weekly dosage can
provide an edge over the daily dosing regimen of GLP-1 products
like Victoza. Currently, Bydureon is the only GLP-1 receptor
agonist which has a once weekly dosing.
However, several big pharma companies like Novo Nordisk
) (Eperzan) have GLP-1 candidates with once weekly dosing in
Eli Lilly is a Zacks Rank #3 (Hold) stock. Some better-ranked
Auxilium Pharmaceuticals Ltd.
) carrying a Zacks Rank #1 (Strong Buy).
AUXILIUM PHARMA (AUXL): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
To read this article on Zacks.com click here.